ABVC BioPharma Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for ABVC BioPharma.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
ABVC BioPharma (NASDAQ:ABVC) Is Carrying A Fair Bit Of Debt
Mar 13
Australian ethics committee approves ABVC's phase 2 study plan for its eye-gel substitute
Oct 05ABVC Biopharma rises on clinical update from Phase 2 trial of ADHD drug
Sep 23ABVC BioPharma (NASDAQ:ABVC) Has Debt But No Earnings; Should You Worry?
Aug 18ABVC BioPharma GAAP EPS of -$0.06 beats by $0.07, revenue of $0.31M beats by $0.3M
Aug 17ABVC Biopharma rises 18% on acceleration of ADHD drug Phase 2 trial
Jul 13Thai ethics committee approves ABVC's phase 2 study protocol for its eye-gel substitute
Jun 30Is ABVC BioPharma (NASDAQ:ABVC) Using Too Much Debt?
Apr 04Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Dec 09Is ABVC BioPharma (NASDAQ:ABVC) A Risky Investment?
Aug 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ABVC BioPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 1 | -8 | -2 | -2 | N/A |
| 6/30/2024 | 0 | -11 | -3 | -3 | N/A |
| 3/31/2024 | 0 | -13 | -3 | -3 | N/A |
| 12/31/2023 | 0 | -11 | -4 | -4 | N/A |
| 9/30/2023 | 1 | -12 | -4 | -4 | N/A |
| 6/30/2023 | 1 | -13 | -3 | -3 | N/A |
| 3/31/2023 | 1 | -12 | -6 | -6 | N/A |
| 12/31/2022 | 1 | -16 | -8 | -7 | N/A |
| 9/30/2022 | 0 | -19 | -10 | -9 | N/A |
| 6/30/2022 | 0 | -18 | -11 | -11 | N/A |
| 3/31/2022 | 0 | -18 | -9 | -9 | N/A |
| 12/31/2021 | 0 | -13 | -8 | -8 | N/A |
| 9/30/2021 | 0 | -10 | -7 | -7 | N/A |
| 6/30/2021 | 0 | -10 | -5 | -5 | N/A |
| 3/31/2021 | 1 | -10 | -5 | -5 | N/A |
| 12/31/2020 | 0 | -10 | -5 | -5 | N/A |
| 9/30/2020 | 1 | -6 | -4 | -4 | N/A |
| 6/30/2020 | 1 | -5 | -4 | -4 | N/A |
| 3/31/2020 | 1 | -4 | -3 | -3 | N/A |
| 12/31/2019 | 1 | -4 | -3 | -3 | N/A |
| 9/30/2019 | 1 | -6 | -1 | -1 | N/A |
| 6/30/2019 | 0 | -6 | -1 | -1 | N/A |
| 3/31/2019 | 0 | -6 | -1 | -1 | N/A |
| 12/31/2018 | 0 | -6 | -1 | -1 | N/A |
| 9/30/2018 | 0 | -2 | -1 | -1 | N/A |
| 6/30/2018 | 0 | -5 | N/A | -1 | N/A |
| 3/31/2018 | N/A | -5 | N/A | -1 | N/A |
| 12/31/2017 | N/A | -4 | N/A | -1 | N/A |
| 9/30/2017 | N/A | -4 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | -1 | N/A |
| 3/31/2017 | N/A | -1 | N/A | -4 | N/A |
| 12/31/2016 | N/A | -8 | N/A | -3 | N/A |
| 9/30/2016 | N/A | -11 | N/A | -3 | N/A |
| 12/31/2015 | N/A | -5 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ABVC's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if ABVC's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if ABVC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ABVC's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ABVC's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ABVC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 03:59 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Marla Marin | Zacks Small-Cap Research |